Gerold Bepler began his tenure as president and chief executive officer of the Barbara Ann Karmanos Cancer Institute in Detroit in February 2010. Prior to coming to Karmanos, Dr. Bepler was director of the Comprehensive Lung Cancer Research Center; department chair of Thoracic Oncology; and program leader of the Lung Cancer Program at the Moffitt Cancer Center in Tampa, FL. He also served as professor of Medicine and Oncology at the University of South Florida. Prior to joining the Moffitt Cancer Center, Dr. Bepler was director of the Lung Cancer Program at Roswell Park Cancer Institute in Buffalo, NY. He also held positions at Duke University Hospital and Durham VA Medical Center.
Dr. Bepler is a native of Germany. He received his medical and doctorate degrees from the Philipps University School of Medicine and Dentistry in Marburg, Germany. His postdoctoral fellowships were completed at the National Cancer Institute, Philipps University and at Duke University Medical Center.
David P. King is chairman and CEO of LabCorp, a leading global life sciences company. King has led LabCorp for more than 10 years; in 2016, the company delivered nearly $9.5 billion in revenue with more than 52,000 employees in approximately 60 countries. Prior to becoming CEO on January 1, 2007, King served as LabCorp’s executive vice president and chief operating officer since 2005. Previously, he served as head of the company’s US LABS/Esoterix division, one of the nation’s leading specialty testing and cancer diagnostic laboratories. King joined LabCorp as senior vice president, general counsel and chief compliance officer in 2001 after serving for several years as the company’s outside counsel. Prior to joining the company, he was a partner with Hogan & Hartson L.L.P. (now Hogan Lovells) in Baltimore, Maryland, from 1992 to 2001, and previously served as a federal prosecutor for the U.S. Department of Justice.
King serves on the boards of Cardinal Health, Inc. (NYSE: CAH), a Fortune 20 healthcare company, and PATH, a nonprofit global health organization. He is a member of the board of the American Clinical Laboratory Association (ACLA) and served as its chair from 2010 to 2014. King also serves on the board of directors of the Seattle Science Foundation and the board of trustees of Elon University in Elon, North Carolina. In 2017, King was appointed to the advisory board for Duke University’s Robert J. Margolis, MD, Center for Health Policy. King, 61, holds an AB degree, cum laude, from Princeton University and a JD degree, cum laude, from the University of Pennsylvania Law School.
Michael J. Campa is one of the scientific co-founders of Grid Therapeutics and has worked closely with Dr. Patz for over 23 years. With early cancer detection being a persistent theme throughout this partnership, Mike has investigated the efficacy of mass spectroscopy-based proteomics, circulating plasma DNA, and autoantibodies. This last category led directly to the discovery of the autoantibody that has become Grid’s lead asset. Before coming to Duke, Mike worked with Kwen-Jen Chang at Burroughs Wellcome Co. in Research Triangle Park, NC. where he explored the roles of the Ras protein family in cancer.
Dr. Campa received his PhD in biochemistry and molecular biology from the University of Florida, in Gainesville, under the direction of Michael Kilberg.